Pyrazolopyrimidine PI3Kδ Inhibitors for Selective B-Cell Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new PI3K inhibitors to treat inflammatory disorders, autoimmune diseases, and cancer, as existing treatments like rituximab and PI3Kγ/δ inhibitors have limitations in efficacy and specificity.
Innovation Solution
Administering a therapeutically effective amount of pyrazolopyrimidine derivatives or their pharmaceutically acceptable salts to patients with specific conditions, targeting PI3Kδ activity to inhibit B-cell activation and proliferation, thereby treating conditions such as idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, vasculitis, systemic lupus erythematosus, and various lymphomas and leukemias.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If rituximab is used to deplete B cells, then B cell depletion is achieved, but the treatment lacks specificity and has limited efficacy in certain autoimmune diseases
Solution Approach 1:
The patent segments the broad B cell depletion approach into a more specific pathway inhibition strategy by targeting PI3Kδ, which is specifically involved in B cell activation and survival signaling. This allows for more precise modulation of B cell function rather than complete depletion, improving treatment specificity while maintaining efficacy in autoimmune diseases.
Solution Approach 2:
The invention changes the therapeutic parameter from complete B cell depletion (rituximab) to selective inhibition of PI3Kδ signaling pathway. This parameter change enables more nuanced control over B cell activation and survival, providing improved treatment specificity for autoimmune conditions while preserving certain immune functions.
2Adaptability or versatility
If PI3Kγ/δ inhibitors are used to treat inflammatory disorders, then some efficacy is achieved, but the inhibitors lack sufficient specificity and have limited effectiveness
Solution Approach 1:
The patent applies local quality by designing a compound that specifically targets PI3Kδ with high selectivity over other PI3K isoforms. The pyrazolopyrimidine derivative structure is optimized to interact with specific residues in the PI3Kδ binding pocket, creating localized specificity at the molecular level while achieving broad therapeutic effectiveness in inflammatory disorders.
Solution Approach 2:
The invention changes the selectivity parameter of PI3K inhibition by developing a compound with enhanced isoform specificity. The pyrazolopyrimidine derivatives demonstrate preferential binding to PI3Kδ compared to other PI3K isoforms, achieving a parameter change from non-selective to selective inhibition, which improves both effectiveness and reliability of treatment.
3Reliability
If existing PI3K inhibitors are administered, then some inhibition of B cell activation occurs, but the inhibitors do not sufficiently reduce autoantibody secretion and disease progression
Solution Approach 1:
The patent changes the efficacy parameter by optimizing the pyrazolopyrimidine derivative structure to achieve more potent PI3Kδ inhibition. The chemical modifications in Formula I are designed to enhance binding affinity and selectivity, resulting in improved inhibition efficacy that translates to greater reduction in autoantibody secretion and disease progression compared to existing inhibitors.
Data Source
AI summary
The present application provides methods of treating PI3Kδ related disorders using compounds of Formula I:or pharmaceutically acceptable salts thereof.